Fred Schaufele, PhD
Professor Emeritus
Ob/Gyn, Reproductive Sciences
School of Medicine

fred.schaufele@ucsf.edu 415-476-7086

The Schaufele laboratory has a long-standing research interest in the mechanisms of action of hormones and their receptors. Emphasis has been on the regulation of global, tissue-specific gene expression patterns by DNA-binding transcription factors, including nuclear receptors, and their co-factors.

Show full bio (220 words) Hide full bio

In the nuclear receptor field, our studies on androgen and estrogen receptors have been oriented towards understanding their basic mechanisms of action and their roles as central regulators of the growth, respectively, of the majority of breast tumors and almost all prostate tumors. This led to the development of high throughput, highly quantitative capabilities for rapidly identifying agents that up- or down-regulate receptor activity. We currently are incorporating that experience into a research program designed to identify new classes of pharmaceuticals for the treatment of advanced prostate cancer. The growth of those tumors is strongly driven by abnormal activation of the androgen receptor. Most of those tumors initially respond to currently available androgen receptor-targeted drugs. But the tumors change over time in ways in which the drugs no longer are effective and, when a patient becomes resistant to all available drugs, the tumor unfortunately becomes lethal. Most tumors that develop such drug ‘resistance’ still rely on androgen receptors for their growth. Our research program is oriented towards creating a new class of drugs that blocks a specific variant of the androgen receptor that arises during the development of treatment resistance but that lacks the binding sites for currently available drugs. The aim of these studies is to prolong the success of prostate cancer treatment, hopefully indefinitely.

Grants and Projects

Show all (24) Hide

  • AR Splice Variants in Castration Resistant Prostate Cancer, GlaxoSmithKline Sponsored Reseach, 2019-2023
  • Diabetes Research Center, NIH, 2002-2021
  • Nutrition and Obesity Research Center, NIH/NIDDK, 2015-2018
  • AR Splice Variants in Castration Resistant Prostate Cancer, Discovery Partnerships with Academia, GlaxoSmithKline, 2015-2016
  • MicroRNAs that Regulate Castration-Resistant Androgen Receptor Activity and Cell Growth, CDMRP ('DOD') Prostate Cancer Research Program, 2014-2016
  • Hyperinsulinemia, Insulin Resistance and Structural Alterations within the Insulin Receptor, Novo Nordisk Diabetes Innovative Award Program, 2012-2013
  • Hyperinsulinemia, Insulin Resistance and Structural Alterations within the Insulin Receptor, UCSF Diabetes Center Pilot Grant, 2011-2012
  • Detection of novel androgenic anabolic activities in urine and serum with a highly sensitive, cost-efficient Androgen Receptor BioAssay, Partnership for Clean Competition, 2009-2012
  • High throughput identification and characterization of novel anti-prostate cancer therapeutics, CDMRP ('DOD') Prostate Cancer Research Program, 2009-2012
  • High throughput imaging of insulin receptor signaling in living cells, UCSF Clinical/Translational Methods Catalyst Award, 2009-2010
  • Transcription factor interactions at the GH promoter, NIH, 1999-2009
  • UCSF High Throughput Microscope, NIH, 2007-2008
  • Temporal and Spatial Dynamics of Androgen Receptor Conformation and Interactions in Prostate Cancer Cells., CDMRP ('DOD') Prostate Cancer Research Program, 2004-2007
  • Novel imaging techniques that compare estrogen receptor structure in tumors and normal tissues of intact living animals, Susan G. Komen Breast Cancer Foundation, 2005-2007
  • Transcription factor compartmentalization and liver-specific gene expression, UCSF Liver Center Pilot and Feasibility Program, 2005-2006
  • Insulin/TZD regulation of protein structure in fat cells, NIH, 2003-2005
  • Cellular imaging technologies for discovering improved breast cancer therapies, CDMRP ('DOD') Breast Cancer Research Program, 2001-2004
  • Novel technologies to identify tissue-selective estrogens, California Breast Cancer Research Program, 2001-2003
  • Dynamic cellular imaging to identify improved anti-estrogens for breast cancer therapy, The Susan G. Komen Breast Cancer Foundation, 2001-2003
  • Structure of factors controlling glucose regulation measured in living cells by Fluorescence Resonance Energy Transfer, UCSF Diabetes Center Pilot Grant, 2002
  • in vivo estradiol, tamoxifen and raloxifene modulation of association/dissociation kinetics for estrogen receptor, interacting co-factors and DNA binding sites, CDMRP ('DOD') Breast Cancer Research Program, 2001-2002
  • Spatiotemporal dynamics of gene regulatory factors in vivo, International Union Against Cancer/American Cancer Society, 1999-2000
  • Spatiotemporal dynamics of protein interaction cascades in vivo, UCSF Research Evaluation and Allocation Committee, 1999-2000
  • A transcription factor domain used selectively in synergistic activation, American Cancer Society, 1994-2000

Publications (61)

Top publication keywords:
Receptors, AndrogenPerformance-Enhancing SubstancesFluorescence Resonance Energy TransferReceptors, EstrogenSpectrometry, FluorescenceCCAAT-Enhancer-Binding Protein-alphaMicroscopy, FluorescenceGrowth HormoneCell NucleusHyperinsulinismProtein Interaction MappingLuminescent ProteinsEstrogen Receptor alphaAnabolic AgentsPituitary Gland

Show all (56 more) Hide